On­coSec shares turn hot as mi­cro­cap re­ports promis­ing PhII da­ta for an I/O one-two punch

Shares of tiny San Diego-based On­coSec Med­ical ig­nit­ed Wednes­day morn­ing when the mi­cro­cap biotech re­port­ed that its lead drug pro­duced promis­ing Phase II melanoma da­ta.

Re­searchers for the com­pa­ny say that a com­bi­na­tion of their drug, Im­munoPulse IL-12, plus Keytru­da (pem­brolizum­ab) pro­duced a 57% pro­gres­sion free re­sponse rate at 15 months among a small group of pa­tients who were deemed “un­like­ly” to re­spond to a PD-1. They say there was a 100% (11/11) du­ra­tion of re­sponse with no me­di­an PFS rate yet de­ter­mined. And that builds on an ear­li­er mark of a 41% com­plete re­sponse rate, which would be im­pres­sive if it con­tin­ues to hold up.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER